Feature

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

A pharmaceutical and life sciences technology, data, and consulting platform, IntegriChain delivers solutions that help companies manage the commercial and financial complexities of bringing therapies to market...

July 21, 2026

Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural...

July 14, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026

Feature

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...

June 16, 2026

NEWS

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

BTIG starts coverage of two TMS companies at buy, sees anticipated psilocybin therapy approval as potential catalyst for both

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

NEWS

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

BTIG starts coverage of two TMS companies at buy, sees anticipated psilocybin therapy approval as potential catalyst for both

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

Dimerix acquires Phase 2-ready asset for acute kidney injury

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Brookline starts Perimeter at buy; PT C$1.54

Just a few of the companies we’ve highlighted along the way

Subscribe